Combining EZH2 and HDAC inhibitors to target castration-resistant prostate cancers.

by Jonathan B Coulter, Hariharan Easwaran
Published 2023-04-01

Combining EZH2 and HDAC inhibitors to target castration-resistant prostate cancers

by Jonathan B. Coulter, Hariharan Easwaran
Published 2023-04-01

Tissue-location-specific transcription programs drive tumor dependencies in colon cancer

by Lijing Yang, Lei Tu, Shilpa Bisht, Yiqing Mao, Daniel Petkovich, Sara-Jayne Thursby, Jinxiao Liang, Nibedita Patel, Ray-Whay Chiu Yen, Tina Largent, Cynthia Zahnow, Malcolm Brock, Kathy Gabrielson, Kevan J. Salimian, Stephen B. Baylin, Hariharan Easwaran
Published 2024-02-01

Evaluating the impact of age on immune checkpoint therapy biomarkers

by Rossin Erbe, Zheyu Wang, Sharon Wu, Joanne Xiu, Neeha Zaidi, Jennifer La, David Tuck, Nathanael Fillmore, Nicolas A. Giraldo, Michael Topper, Stephen Baylin, Marc Lippman, Claudine Isaacs, Reva Basho, Ilya Serebriiskii, Heinz-Josef Lenz, Igor Astsaturov, John Marshall, Josephine Taverna, Jerry Lee, Elizabeth M. Jaffee, Evanthia T. Roussos Torres, Ashani Weeraratna, Hariharan Easwaran, Elana J. Fertig
Published 2021-08-01

Evaluating the impact of age on immune checkpoint therapy biomarkers

by Rossin Erbe, Zheyu Wang, Sharon Wu, Joanne Xiu, Neeha Zaidi, Jennifer La, David Tuck, Nathanael Fillmore, Nicolas A. Giraldo, Michael Topper, Stephen Baylin, Marc Lippman, Claudine Isaacs, Reva Basho, Ilya Serebriiskii, Heinz-Josef Lenz, Igor Astsaturov, John Marshall, Josephine Taverna, Jerry Lee, Elizabeth M. Jaffee, Evanthia T. Roussos Torres, Ashani Weeraratna, Hariharan Easwaran, Elana J. Fertig
Published 2021-11-01